Our latest study explores patient confidence in interpreting ketone test results, DKA risk perceptions, and real-world testing behaviors in adults with type 1 Diabetes.
This survey shows COVID-19 booster rates are higher in U.S. adults with diabetes than the general population, but vary by race, income, and location.
Our survey finds major pharmacies often fail people with diabetes, with wide NPS score gaps; Sam’s Club, Publix, Costco, and U.S. Medical Supply rank highest.
We surveyed panel members about the FDA advisory on Provention Bio’s teplizumab to delay type 1 diabetes—discover their top concerns and expected impact.
This research reveals how stigma in diabetes—from HCPs and society—affects relationships, care decisions, mental health, and diabetes management.
ADA and dQ&A survey results reveal that COVID fears kept one in five people with diabetes away from the doctor during the pandemic.
Which diabetes groups lead or lag on COVID-19 shots? See dQ&A’s panel results from March 2021 and uncover barriers to higher coverage.
5,700 dQ&A community members share where they were diagnosed, first symptoms, and emotions—highlighting key differences between type 1 and type 2 journeys.
Part 2 of dQ&A’s CGM series digs into adoption barriers and the Ambulatory Glucose Profile, which can help people make sense of the data CGMs provide.
